Funding Round attributes
Cytovale, a medical diagnostics company, has successfully raised $100 million in a Series D funding round. This investment is intended to accelerate the commercial expansion of its IntelliSep sepsis diagnostic tool, which has received FDA clearance. IntelliSep is designed for rapid detection of sepsis, offering results in approximately eight minutes, allowing for quicker diagnosis and treatment in emergency departments. Sepsis, a life-threatening condition caused by the body’s response to infection, is a leading cause of death in hospitals, making early diagnosis critical.
The Series D funding round was led by Sands Capital, with new investment from the Canada Pension Plan Investment Board and continued support from existing investors such as Norwest Venture Partners, Global Health Investment Corporation, and Breakout Ventures. The influx of capital will enable Cytovale to scale IntelliSep's availability across more hospitals nationwide, with a particular focus on emergency departments, where the majority of sepsis cases are first identified.
